U.S. markets open in 6 hours 8 minutes
  • S&P Futures

    4,478.50
    +4.25 (+0.09%)
     
  • Dow Futures

    34,800.00
    +51.00 (+0.15%)
     
  • Nasdaq Futures

    15,525.25
    +7.50 (+0.05%)
     
  • Russell 2000 Futures

    2,230.20
    +2.30 (+0.10%)
     
  • Crude Oil

    72.29
    -0.32 (-0.44%)
     
  • Gold

    1,763.50
    +6.80 (+0.39%)
     
  • Silver

    22.97
    +0.17 (+0.75%)
     
  • EUR/USD

    1.1787
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.69
    +0.51 (+2.81%)
     
  • GBP/USD

    1.3796
    -0.0000 (-0.00%)
     
  • USD/JPY

    109.8380
    +0.1200 (+0.11%)
     
  • BTC-USD

    47,969.30
    -446.77 (-0.92%)
     
  • CMC Crypto 200

    1,227.40
    -5.89 (-0.48%)
     
  • FTSE 100

    7,072.83
    +45.35 (+0.65%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study evaluating pelareorep plus checkpoint blockade therapy.

  • These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.

  • Data from 20 HR+/HER2- early-stage breast cancer patients included in AWARE-1's first two cohorts are presented.

  • These patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) Roche's PD-L1 inhibitor atezolizumab (Tecentriq) before surgery.

  • Pelareorep treatment in cohort 1 induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ T cells, and increased the CelTIL score, a measure of tumor cellularity and inflammation associated with favorable clinical outcomes.

  • Data from cohort 2 patients demonstrated that pelareorep and atezolizumab generated an anti-cancer immune response in the tumor and peripheral blood.

  • Notably, cohort 2 met the pre-specified success criteria for the study's primary endpoint (50% of patients with over 30% increase in CelTIL score)—six of ten patients achieved at least a 30% increase in CelTIL score following treatment.

  • Pelareorep reversed immunosuppressive tumor microenvironments and promoted immune effector cell infiltration into solid tumors.

  • Tumor-cell-specific pelareorep replication was observed in all evaluated patients following intravenous pelareorep administration.

  • 70% of all cohort 1 and 2 patients (n=20) saw an increase in CelTIL from baseline to surgery.

  • Compared to cohort 1, cohort 2 patients had a higher ratio of CD8+ T cells to regulatory T cells, suggesting pelareorep and checkpoint inhibition enhance inflammation within the tumor microenvironment.

  • Oncolytics will host a Key Opinion Leader event today at 2:00 pm E.T.

  • Price Action: ONCY shares are down 8.9% at $3.65 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.